EUVIMEDEUVIMED entdecken
Open Access

Models using comprehensive, lesion-level, longitudinal [68Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [177Lu]Lu-DOTA-TATE

Victor Santoro-Fernandes, Brayden Schott, Ali Deatsch, Quinton Keigley, Thomas Francken, Renuka Iyer, Christos Fountzilas, Scott Perlman, Robert Jeraj iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06767-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Victor Santoro-Fernandes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. vfernandes@wisc.edu. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Organometallic Compounds. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of Wisconsin Carbone Cancer Center, Roswell Park Comprehensive Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Somatostatin receptor (SSTR) imaging features are predictive of treatment outcome for neuroendocrine tumor (NET) patients receiving peptide receptor radionuclide therapy (PRRT). However, comprehensive (all metastatic lesions), longitudinal (temporal variation), and lesion-level measured features have never been explored. Such features allow for capturing the heterogeneity in disease response to treatment. Furthermore, models combining these features are lacking. In this work we evaluated the predictive power of comprehensive, longitudinal, lesion-level 68GA-SSTR-PET features combined with a multivariate linear regression (MLR) model. METHODS: This retrospective study enrolled NET patients treated with [177Lu]Lu-DOTA-TATE and imaged with [68Ga]Ga-DOTA-TATE at baseline and post-therapy. All lesions were segmented, anatomically labeled, and longitudinally matched. Lesion-level uptake and variation in uptake were measured. Patient-level features were engineered and selected for modeling of progression-free survival (PFS). The model was validated via concordance index, patient classification (ROC analysis), and survival analysis (Kaplan-Meier and Cox proportional hazards). The MLR was benchmarked against single feature predictions. RESULTS: Thirty-six NET patients were enrolled and stratified into poor and good responders (PFS ≥ 25 months). Four patient-level features were selected, the MLR concordance index was 0.826, and the AUC was 0.88 (0.85 specificity, 0.81 sensitivity). Survival analysis led to significant patient stratification (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotideOrganometallic CompoundsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeAdultPositron-Emission TomographyPrognosisLongitudinal Studies

Stichwörter der Autor:innen

Neuroendocrine tumorOutcome predictionPeptide receptor radionuclide therapySomatostatin receptor imagingTreatment response assessment

Substanzen

OctreotideOrganometallic Compoundslutetium Lu 177 dotatategallium Ga 68 dotatate

Autor:innen und Institutionen

  • Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. vfernandes@wisc.edu.
  • Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
  • Section of Nuclear Medicine and Molecular Imaging, Department of Radiology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
  • Division of GI Medicine, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Carbone Cancer Centre, University of Wisconsin, Madison, WI, USA.
  • Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. rjeraj@wisc.edu.

ORCID-Profile: Robert Jeraj

Förderung

  • NCI NIH HHS
  • University of Wisconsin Carbone Cancer Center
  • Roswell Park Comprehensive Cancer Center

Zitieren

APA

Santoro-Fernandes, V., Schott, B., Deatsch, A., Keigley, Q., Francken, T., Iyer, R., Fountzilas, C., Perlman, S., & Jeraj, R. (2024). Models using comprehensive, lesion-level, longitudinal [68Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [177Lu]Lu-DOTA-TATE. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06767-x

Vancouver

Santoro-Fernandes V, Schott B, Deatsch A, Keigley Q, Francken T, Iyer R, et al. Models using comprehensive, lesion-level, longitudinal [68Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [177Lu]Lu-DOTA-TATE. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06767-x

BibTeX
@article{SantoroFernandes2024,
  author = {Santoro-Fernandes, Victor and Schott, Brayden and Deatsch, Ali and Keigley, Quinton and Francken, Thomas and Iyer, Renuka and Fountzilas, Christos and Perlman, Scott and Jeraj, Robert},
  title = {Models using comprehensive, lesion-level, longitudinal [68Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [177Lu]Lu-DOTA-TATE},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06767-x}
}
Kostenlos starten →